GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion
US FDA Sets May 2023 Decision Date For RSV Vaccine
GSK could have its RSV vaccine on the US market by mid-2023 - but is likely to be accompanied by rival Pfizer. • Source: GSK 
